It’s an Exciting Time for Psoriasis

“It’s an exciting time. We’re not just managing chronic disease—we’re reimagining its trajectory.”

Join Dr. Mona Shahriari of Central Connecticut Dermatology and NPF Medical Board member, as she discusses the latest from the AAD Annual Meeting: head-to-head studies between IL-17 and IL-23 inhibitors, early intervention in psoriasis, the use of GLP-1s, new TYK2s and oral IL-23 inhibitors, and treating high-impact sites—with moderator Archie Franklin.